1887

Abstract

Congenital cytomegalovirus (cCMV) is a leading cause of birth defects. The guinea pig is the only small cCMV animal model. Guinea pig cytomegalovirus (GPCMV) encodes similar glycoprotein complexes to human CMV (HCMV) including gB and the gH-based pentamer complex (PC). In HCMV, both gB and PC are neutralizing antibody antigens. The relevance of GPCMV PC for virus tropism and vaccine target remains controversial. A novel guinea pig placental amniotic sac epithelial (GPASE) cell-line did not express viral cell receptor platelet derived growth factor receptor alpha (PDGFRA) and resulted in requirement for the PC for GPCMV infection unless PDGFRA was ectopically expressed. High titer anti-gB sera from a GPCMV gB vaccine study was evaluated for GPCMV neutralizing capability on GPASE cells in comparison to convalescent sera from GPCMV(PC+) or GPCMV(PC-) infected animals. Anti-gB sera neutralized fibroblast infection but was less effective compared to anti-GPCMV(PC-), which had antibodies to gH/gL. However, both anti-GPCMV(PC-) and anti-gB sera similarly had reduced neutralizing capability on GPASE and renal epithelial cells in comparison to anti-GPCMV(PC+) sera, which had additional antibodies to PC. Overall, results demonstrate the importance of the PC for GPCMV tropism to various cell types that lack PDGFRA expression and the limited ability of anti-gB sera to neutralize GPCMV on non-fibroblast cells despite the essential nature of gB glycoprotein.

Funding
This study was supported by the:
  • Alistair McGregor , National Institute of Child Health and Human Development , (Award R01HD090065)
  • Alistair McGregor , National Institute of Allergy and Infectious Diseases , (Award R01AI100933)
  • Alistair McGregor , National Institute of Allergy and Infectious Diseases , (Award R01AI098984)
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001394
2020-02-18
2020-06-02
Loading full text...

Full text loading...

/deliver/fulltext/jgv/101/4/426.html?itemId=/content/journal/jgv/10.1099/jgv.0.001394&mimeType=html&fmt=ahah

References

  1. Cannon MJ, Griffiths PD, Aston V, Rawlinson WD. Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?. Rev Med Virol 2014; 24:291–307 [CrossRef][PubMed]
    [Google Scholar]
  2. Morton CC, Nance WE. Newborn hearing screening — a silent revolution. N Engl J Med 2006; 354:2151–2164 [CrossRef]
    [Google Scholar]
  3. Enders G, Daiminger A, Bäder U, Exler S, Enders M. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 2011; 52:244–246 [CrossRef][PubMed]
    [Google Scholar]
  4. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev 2013; 26:86–102 [CrossRef][PubMed]
    [Google Scholar]
  5. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289:1008–1011 [CrossRef]
    [Google Scholar]
  6. Britt WJ. Congenital human cytomegalovirus infection and the enigma of maternal immunity. J Virol 2017; 91: [CrossRef]
    [Google Scholar]
  7. Lilleri D, Fornara C, Furione M, Zavattoni M, Revello MG et al. Development of human Cytomegalovirus–Specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J Infect Dis 2007; 195:1062–1070 [CrossRef]
    [Google Scholar]
  8. Boppana SB, Britt WJ. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 1995; 171:1115–1121 [CrossRef][PubMed]
    [Google Scholar]
  9. Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One 2013; 8:e59863 [CrossRef]
    [Google Scholar]
  10. Lilleri D, Gerna G. Maternal immune correlates of protection from human cytomegalovirus transmission to the fetus after primary infection in pregnancy. Rev Med Virol 2017; 27:e1921 [CrossRef]
    [Google Scholar]
  11. Johnson KP. Mouse cytomegalovirus: placental infection. J Infect Dis 1969; 120:445–450 [CrossRef][PubMed]
    [Google Scholar]
  12. Kaufmann P. Guinea Pig Cavia procellus. Benirschke KEditorComparitive Placentation 2004
    [Google Scholar]
  13. Carter AM. Animal models of human placentation – a review. Placenta 2007; 28:S41–S47 [CrossRef]
    [Google Scholar]
  14. Mess A. The guinea pig placenta: model of placental growth dynamics. Placenta 2007; 28:812–815 [CrossRef]
    [Google Scholar]
  15. Griffith BP, McCormick SR, Fong CK, Lavallee JT, Lucia HL et al. The placenta as a site of cytomegalovirus infection in guinea pigs. J Virol 1985; 55:402–409 [CrossRef]
    [Google Scholar]
  16. Kumar ML, Nankervis GA. Experimental congenital infection with cytomegalovirus: a guinea pig model. J Infect Dis 1978; 138:650–654 [CrossRef][PubMed]
    [Google Scholar]
  17. Woolf NK. Guinea pig model of congenital CMV-induced hearing loss: a review. Transplant Proc 1991; 23:32–34[PubMed]
    [Google Scholar]
  18. Choi YC, Hsiung GD. Cytomegalovirus infection in guinea pigs. II. transplacental and horizontal transmission. J Infect Dis 1978; 138:197–202 [CrossRef][PubMed]
    [Google Scholar]
  19. Coleman S, Hornig J, Maddux S, Choi KY, McGregor A. Viral glycoprotein complex formation, essential function and immunogenicity in the guinea pig model for cytomegalovirus. PLoS One 2015; 10:e0135567 [CrossRef]
    [Google Scholar]
  20. Choi KY, Root M, McGregor A. A novel non-replication-competent cytomegalovirus capsid mutant vaccine strategy is effective in reducing congenital infection. J Virol 2016; 90:7902–7919 [CrossRef][PubMed]
    [Google Scholar]
  21. Kinzler ER, Compton T. Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J Virol 2005; 79:7827–7837 [CrossRef]
    [Google Scholar]
  22. Coleman S, Choi KY, Root M, McGregor A. A homolog pentameric complex dictates viral epithelial tropism, pathogenicity and congenital infection rate in guinea pig cytomegalovirus. PLoS Pathog 2016; 12:e1005755 [CrossRef][PubMed]
    [Google Scholar]
  23. Coleman S, Choi KY, McGregor A. Cytomegalovirus UL128 homolog mutants that form a pentameric complex produce virus with impaired epithelial and trophoblast cell tropism and altered pathogenicity in the guinea pig. Virology 2017; 509:205–221 [CrossRef]
    [Google Scholar]
  24. Miura T, Makino R, Yamada K, Matsuura M, Okumura M et al. Differences in the effects of mutations in GP131, a guinea pig cytomegalovirus homologue of pentameric complex component UL130, on macrophage and epithelial cell infection. J Gen Virol 2018; 99:1425–1431 [CrossRef]
    [Google Scholar]
  25. Kabanova A, Marcandalli J, Zhou T, Bianchi S, Baxa U et al. Platelet-Derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. Nat Microbiol 2016; 1:16082 [CrossRef]
    [Google Scholar]
  26. Wu Y, Prager A, Boos S, Resch M, Brizic I et al. Human cytomegalovirus glycoprotein complex gH/gL/gO uses PDGFR-α as a key for entry. PLoS Pathog 2017; 13:e1006281 [CrossRef]
    [Google Scholar]
  27. Choi KY, El-Hamdi NS, McGregor A. Inclusion of the viral pentamer complex in a vaccine design greatly improves protection against congenital cytomegalovirus in the guinea pig model. J Virol 2019; 93: [CrossRef]
    [Google Scholar]
  28. Martinez-Martin N, Marcandalli J, Huang CS, Arthur CP, Perotti M et al. An unbiased screen for human cytomegalovirus identifies neuropilin-2 as a central viral receptor. Cell 2018; 174:e191158–1171 [CrossRef]
    [Google Scholar]
  29. McGregor A, Schleiss MR. Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli . Mol Genet Metab 2001; 72:15–26 [CrossRef]
    [Google Scholar]
  30. Cui X, McGregor A, Schleiss MR, McVoy MA. Cloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication. J Virol Methods 2008; 149:231–239 [CrossRef]
    [Google Scholar]
  31. Schleiss MR, McGregor A, Choi KY, Date SV, Cui X et al. Analysis of the nucleotide sequence of the guinea pig cytomegalovirus (GPCMV) genome. Virol J 2008; 5:139 [CrossRef]
    [Google Scholar]
  32. Miki T, Marongiu F, Dorko K, Ellis EC, Strom SC. Isolation of amniotic epithelial stem cells. Curr Protoc Stem Cell Biol 2010; Chapter 1:
    [Google Scholar]
  33. Xing Z, McFarland CT, Sallenave JM, Izzo A, Wang J et al. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One 2009; 4:e5856 [CrossRef]
    [Google Scholar]
  34. Yue Y, Zhou SS, Barry PA. Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques. J Gen Virol 2003; 84:3371–3379 [CrossRef][PubMed]
    [Google Scholar]
  35. Ryckman BJ, Chase MC, Johnson DC. Hcmv gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors. Proc Natl Acad Sci USA 2008; 105:14118–14123 [CrossRef]
    [Google Scholar]
  36. Britt WJ, Harrison C. Identification of an abundant disulfide-linked complex of glycoproteins in the envelope of guinea pig cytomegalovirus. Virology 1994; 201:294–302 [CrossRef]
    [Google Scholar]
  37. Roubelakis MG, Trohatou O, Anagnou NP. Amniotic fluid and amniotic membrane stem cells: marker discovery. Stem Cells Int 2012; 2012:1078369 [CrossRef][PubMed]
    [Google Scholar]
  38. Hornig J, Choi KY, McGregor A. The essential role of guinea pig cytomegalovirus (GPCMV) IE1 and IE2 homologs in viral replication and IE1-mediated ND10 targeting. Virology 2017; 504:122–140 [CrossRef]
    [Google Scholar]
  39. Choi KY AM. A New Strain of Guinea Pig CMV Suggests a More Prudent Strategy for Evaluation of Interventions Against Congenital CMV. Abstract # B-OP-018. 6th International Congenital CMV Conference/ 16th International CMV/betaherpesvirus Workshop The Netherlands: Noordwijkerhout; 2017
    [Google Scholar]
  40. Tabata T, Petitt M, Fang-Hoover J, Zydek M, Pereira L. Persistent cytomegalovirus infection in amniotic membranes of the human placenta. Am J Pathol 2016; 186:2970–2986 [CrossRef]
    [Google Scholar]
  41. El-Hamdi NS, Choi KY AM. Platelet-derived growth factor-alpha receptor (PDGFRA) is the cell receptor for guinea pig cytomegalovirus fibroblast infection but not for trophoblast or congenital disease. Abstract# W3-12. 38th Annual Meeting American Society for Virology MN USA: Minneapolis; 2019
    [Google Scholar]
  42. Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ et al. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 2004; 189:1374–1381 [CrossRef]
    [Google Scholar]
  43. Feire AL, Koss H, Compton T. Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain. Proc Natl Acad Sci USA 2004; 101:15470–15475 [CrossRef]
    [Google Scholar]
  44. Wussow F, Yue Y, Martinez J, Deere JD, Longmate J et al. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol 2013; 87:1322–1332 [CrossRef]
    [Google Scholar]
  45. Abel K, Martinez J, Yue Y, Lacey SF, Wang Z et al. Vaccine-Induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. J Virol 2011; 85:2878–2890 [CrossRef]
    [Google Scholar]
  46. Albiero E, Amati E, Baumeister E, Einsele H, Grigoleit GU et al. Heterogeneity of specific CD4+ and CD8+ T cells stimulated by CMV pp65 and IE1 antigens. J Immunother 2016; 39:329–342 [CrossRef][PubMed]
    [Google Scholar]
  47. Pass RF. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J Clin Virol 2009; 46:S73–S76 [CrossRef][PubMed]
    [Google Scholar]
  48. Pass RF, Zhang C, Evans A, Simpson T, Andrews W et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360:1191–1199 [CrossRef]
    [Google Scholar]
  49. Cui X, Meza BP, Adler SP, McVoy MA. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008; 26:5760–5766 [CrossRef]
    [Google Scholar]
  50. Schleiss MR, Choi KY, Anderson J, Mash JG, Wettendorff M et al. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model. Vaccine 2014; 32:2756–2762 [CrossRef]
    [Google Scholar]
  51. Schleiss MR, Bourne N, Bernstein DI. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis 2003; 188:1868–1874 [CrossRef]
    [Google Scholar]
  52. Swanson EC, Gillis P, Hernandez-Alvarado N, Fernández-Alarcón C, Schmit M et al. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (gp83) vaccine for congenital cytomegalovirus infection in a guinea pig model: inclusion of gp83 reduces GB antibody response but both vaccine approaches provide equivalent protection against pup mortality. Vaccine 2015; 33:4013–4018 [CrossRef][PubMed]
    [Google Scholar]
  53. Cardin RD, Bravo FJ, Pullum DA, Orlinger K, Watson EM et al. Replication-Defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection. Vaccine 2016; 34:1993–1999 [CrossRef][PubMed]
    [Google Scholar]
  54. Cui X, Cao Z, Wang S, Lee RB, Wang X et al. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response. Vaccine 2018; 36:5580–5590 [CrossRef]
    [Google Scholar]
  55. Contreras H, Wussow F, Fernández-Alarcón C, Bierle C, Nguyen J et al. MVA-Vectored pentameric complex (PC) and gB vaccines improve pregnancy outcome after guinea pig CMV challenge, but only gB vaccine reduces vertical transmission. Vaccines 2019; 7:182 [CrossRef]
    [Google Scholar]
  56. Ha S, Li F, Troutman MC, Freed DC, Tang A et al. Neutralization of diverse human cytomegalovirus strains conferred by antibodies targeting viral gH/gL/pUL128-131 pentameric complex. J Virol 2017; 91: [CrossRef]
    [Google Scholar]
  57. Chiuppesi F, Wussow F, Johnson E, Bian C, Zhuo M et al. Vaccine-Derived neutralizing antibodies to the human cytomegalovirus gH/gL pentamer potently block primary cytotrophoblast infection. J Virol 2015; 89:11884–11898 [CrossRef]
    [Google Scholar]
  58. Loughney JW, Rustandi RR, Wang D, Troutman MC, Dick LW et al. Soluble human cytomegalovirus gH/gL/pUL128-131 pentameric complex, but not gH/gL, inhibits viral entry to epithelial cells and presents dominant native neutralizing epitopes. J Biol Chem 2015; 290:15985–15995 [CrossRef][PubMed]
    [Google Scholar]
  59. Murrell I, Bedford C, Ladell K, Miners KL, Price DA et al. The pentameric complex drives immunologically covert cell–cell transmission of wild-type human cytomegalovirus. Proc Natl Acad Sci USA 2017; 114:6104–6109 [CrossRef]
    [Google Scholar]
  60. Tabata T, Petitt M, Fang-Hoover J, Freed DC, Li F et al. Neutralizing monoclonal antibodies reduce human cytomegalovirus infection and spread in developing placentas. Vaccines 2019; 7:135 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001394
Loading
/content/journal/jgv/10.1099/jgv.0.001394
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error